Acerus Pharmaceuticals (OTCMKTS:ASPCF) Stock Price Down 6.3%

Acerus Pharmaceuticals Co. (OTCMKTS:ASPCF)’s share price was down 6.3% during trading on Friday . The company traded as low as $0.05 and last traded at $0.05, approximately 100 shares changed hands during trading. A decline of 99% from the average daily volume of 7,887 shares. The stock had previously closed at $0.05.

The business has a 50-day moving average of $0.04 and a 200 day moving average of $0.04. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.72 and a current ratio of 2.94.

Acerus Pharmaceuticals (OTCMKTS:ASPCF) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.01) EPS for the quarter. The firm had revenue of $0.15 million for the quarter.

Acerus Pharmaceuticals Company Profile (OTCMKTS:ASPCF)

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia.

See Also: What is a Stop Order?

Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.